Actions

CD38: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 19: Line 19:


----
----
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|<span style="font-size:100%">'''Expression in primitive cell types'''</font>
|-
! AML !! CMML !! B ALL !! Burkitt || T ALL !! ETP ALL <'''[[ETP ALL|I]]'''> !! MPAL <'''[[MPAL|I]]'''> || Hgns <'''[[Hgns|I]]'''>
|-
|style="width: 12.5%; background: #66e0ff; color:black"|20-40%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|-
|}
<span style="font-size:90%">'''Notes:''' In aml CD14 expression defines monocytic lineage restriction but may be absent especially in more primitive monoblastic cases  </span>
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in mature B cell neoplasms'''
|-
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|-
|}
<span style="font-size:90%">'''Notes:''' Low level expression has been reported on activated lymphocytes, but it has no definite diagnostic role </span>
{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
!colspan="7"|'''Expression in mature T cell neoplasms'''
|-
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|-
|}
----


<span style="color:navy">'''''SUMMARY TABLES'''''</span>
<span style="color:navy">'''''SUMMARY TABLES'''''</span>

Revision as of 10:22, 8 May 2023



DETAILS

CD38 helps mobilise intracellular calcium to activate a wide array of cell functions. In haematological cell types CD38 it is widely expressed by lymphoid cells )B, T and NK) as well as myeloid precursor cells and mature myeloid cells. It has particular diagnostic importance for lymphocytes where CD38 expression is acquired as stem cells commit to B-cell lineage, then is lost as mature B cells emerge from bone marrow before being re-acquired at the time of plasma cell differentiation.


What is its diagnostic role?

The wide expression of CD38 limits its diagnostic value except in very specific circumstances:

  • The co-expression of CD38 with CD138 can identify normal or neoplastic plasma cells
  • Expression of CD38 in chronic lymphocytic leukaemia (>20% of cells) may associated with poorer outcome


Other relevant information: CD38 is a therapeutic target, daratumumab is a monoclonal antibody which binds to CD38 and is used in the treatment of myeloma.



Expression in primitive cell types
AML CMML B ALL Burkitt T ALL ETP ALL <I> MPAL <I> Hgns <I>
20-40% 80-100% <5% <5% <5% <5% <5% <5%

Notes: In aml CD14 expression defines monocytic lineage restriction but may be absent especially in more primitive monoblastic cases


Expression in mature B cell neoplasms
CLL MCL FL MZL HCL DLBCL LPL PCL
<5% <5% <5% <5% <5% <5% <5% <5%

Notes: Low level expression has been reported on activated lymphocytes, but it has no definite diagnostic role


Expression in mature T cell neoplasms
ATLL CTCL/Sezary T-PLL T-LGL NK-LGL
<5% <5% <5% <5% <5%




SUMMARY TABLES

Expression of CD38 by primitive lymphoid cells: ALL and haematogones
pro-B ALL early pre-B ALL pre-B ALL B-ALL pro-T ALL mature-T ALL AML Haematogones
* stg

* low expression correlates with subtype e.g. APML

Expression of CD38 by mature B cells: B-lymphoproliferative disorders
CLL MCL FL HCL HCv MZL LPL PCL
* ** stg/mod

*May indicate adverse prognostic when present on more than 20% of cells

**May be weak


1. Colour key: - the likelihood of any individual case expressing this marker, indicated by colour:

Rare (<5%) Possible (5-20%) Likely (20-40%) Frequent (40-80%) Expected (80-100%)

2. Text key: - where expression level is characteristic of a disorder this is indicated by text:

abs = absent expression, wk = weak expression, mod = moderate expression, stg = strong expression, sub = expression may be on a sub-population of cells